What is Wedbush's Estimate for DAWN FY2028 Earnings?

Key Points

• Wedbush raised its FY2028 earnings per share (EPS) estimate for Day One Biopharmaceuticals from $0.47 to $0.56, while maintaining an "Outperform" rating and a $25.00 price target.
• Day One Biopharmaceuticals recently reported a quarterly EPS of ($0.29), exceeding the consensus estimate of ($0.35) and showing revenue of $33.91 million.
• Institutional investors and hedge funds own 87.95% of Day One Biopharmaceuticals' stock, highlighting strong institutional interest in the company.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Investment analysts at Wedbush upped their FY2028 earnings per share (EPS) estimates for shares of Day One Biopharmaceuticals in a report released on Tuesday, August 5th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $0.56 per share for the year, up from their prior forecast of $0.47. Wedbush has a "Outperform" rating and a $25.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals' FY2029 earnings at $1.53 EPS.

DAWN has been the subject of several other reports. HC Wainwright reduced their price target on Day One Biopharmaceuticals from $36.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday. Needham & Company LLC decreased their price target on Day One Biopharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $25.33.

Day One Biopharmaceuticals Trading Up 4.0%

Shares of DAWN traded up $0.23 during trading hours on Thursday, hitting $6.03. The company had a trading volume of 198,153 shares, compared to its average volume of 1,348,449. The company has a market capitalization of $611.61 million, a PE ratio of -6.32 and a beta of -1.26. Day One Biopharmaceuticals has a one year low of $5.64 and a one year high of $16.76. The company's fifty day moving average price is $6.71 and its two-hundred day moving average price is $8.14.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.06. The firm had revenue of $33.91 million during the quarter, compared to analyst estimates of $35.55 million. Day One Biopharmaceuticals had a negative return on equity of 18.53% and a negative net margin of 50.63%.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, General Counsel Adam Dubow sold 4,552 shares of the company's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $28,495.52. Following the sale, the general counsel owned 47,136 shares in the company, valued at $295,071.36. This represents a 8.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Charles N. York II sold 4,282 shares of the company's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $26,805.32. Following the completion of the transaction, the chief financial officer directly owned 265,231 shares of the company's stock, valued at $1,660,346.06. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,725 shares of company stock worth $167,299. 6.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of large investors have recently bought and sold shares of DAWN. FMR LLC raised its holdings in Day One Biopharmaceuticals by 73.9% in the 4th quarter. FMR LLC now owns 12,887,467 shares of the company's stock worth $163,284,000 after purchasing an additional 5,475,087 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $31,829,000. Boxer Capital Management LLC acquired a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $15,077,000. Vestal Point Capital LP raised its holdings in shares of Day One Biopharmaceuticals by 80.4% during the first quarter. Vestal Point Capital LP now owns 2,598,127 shares of the company's stock valued at $20,603,000 after acquiring an additional 1,158,127 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Day One Biopharmaceuticals by 587.2% in the first quarter. Millennium Management LLC now owns 1,320,095 shares of the company's stock valued at $10,468,000 after purchasing an additional 1,127,995 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.